Islet transplantation in type 1 diabetes: Ongoing challenges, refined procedures, and long-term outcome

Review of Diabetic Studies

Volumn 9, Issue 4, 2012, Pages 385-406

  James Shapiro, A M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Allograft; Diabetes; Immunosuppression; Islet; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; AMINOTRANSFERASE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD3 ANTIBODY; CONTRAST MEDIUM; CYCLOSPORIN; DACLIZUMAB; DIPHENHYDRAMINE; EFALIZUMAB; ENOXAPARIN; ETANERCEPT; EXENDIN 4; HEMOGLOBIN A1C; HEPARIN; LIRAGLUTIDE; MICROCRYSTALLINE COLLAGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SULFAMETHOXAZOLE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETHOPRIM; UNINDEXED DRUG; VALGANCICLOVIR; WARFARIN;

APOPTOSIS; APPLICATION SITE DISCOMFORT; BLEEDING; CHIBA NEEDLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EDEMA; FATIGUE; FATTY LIVER; FLUOROSCOPY; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; MOUTH ULCER; NAUSEA; NONHUMAN; OVARY CYST; PAIN; PANCREAS ISLET TRANSPLANTATION; PARTIAL THROMBOPLASTIN TIME; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PORTAL PHLEBOGRAPHY; PORTAL VEIN; PORTAL VEIN THROMBOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ACCESS; VASCULAR GUIDE WIRE; VEIN OCCLUSION;

EID: 84888155347     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2012.9.385     Document Type: Review

References (256)

1. Shapiro AM, Rocirdi C. Islet cell transplantation-indications, risks and long-term outcomes. In: Kirk AD (editor). Textbook of organ transplantation. Wiley-Blackwell, 2013, in press.
2. Shapiro AM, Rocirdi C. The transplant procedure and surgical technique: islet transplantation. In: Kirk AD (editor). Textbook of organ transplantation. Wiley-Blackwell, 2013, in press.
3. O'Reilly M, O'Sullivan EP, Davenport C, Smith D. "Dead in bed": a tragic complication of type 1 diabetes mellitus. Irish J Med Sci 2010. 179(4):585-587.
4. Koltin D, Daneman D. Dead-in-bed syndrome-a diabetes nightmare. Pediatr Diabetes 2008. 9(5):504-507.
5. Hanas R. Dead-in-bed syndrome in diabetes mellitus and hypoglycaemic unawareness. Lancet 1997. 350(9076):492-493.
6. Campbell LK, Gonder-Frederick LA, Broshek DK, Kovatchev BP, Anderson S, Clarke WL, Cox DJ. Neurocognitive differences between drivers with type 1 diabetes with and without a recent history of recurrent driving mishaps. Int J Diabetes Mellit 2010. 2(2):73-77.
7. Williams P. Notes on diabetes treated with extract and by grafts of sheep's pancreas. BMJ 1894. 2:1303.
8. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972. 72(2):175-186.
9. Ballinger WF, Lacy PE, Scharp DW, Kemp CB, Knight M. Isografts and allografts of pancreatic islets in rats. Br J Surg 1973. 60(4):313.
10. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989. 38(Suppl 1):140-142.
11. Robertson GS, Chadwick DR, Contractor H, James RF, Bell PR, London NJ. The use of continuous density gradients for the assessment of islet and exocrine tissue densities and islet purification. Acta Diabetol 1993. 30(3):175-180.
12. Yamamoto T, Horiguchi A, Ito M, Nagata H, Ichii H, Ricordi C, Miyakawa S. Quality control for clinical islet transplantation: organ procurement and preservation, the islet processing facility, isolation, and potency tests. J Hepatobiliary Pancreat Surg 2009. 16(2):131-136.
13. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, Marchetti P, Gingerich RL, Jaffe AS, Cryer PE, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990. 39(4):515-518.
14. Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, Matas AJ, Goetz FC. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 1980. 192(4):526-542.
15. Tzakis AG, Ricordi C, Alejandro R, Zeng Y, Fung JJ, Todo S, Demetris AJ, Mintz DH, Starzl TE. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990. 336(8712):402-405.
16. Ricordi C, Tzakis AG, Carroll PB, Zeng YJ, Rilo HL, Alejandro R, Shapiro A, Fung JJ, Demetris AJ, Mintz DH, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992. 53(2):407-414.
17. Bretzel RG, Brandhorst D, Brandhorst H, Eckhard M, Ernst W, Friemann S, Rau W, Weimar B, Rauber K, Hering BJ, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999. 77(1):140-143.
18. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000. 343(4):230-238.
19. Center CC. Seventh Annual Report Collaborative Islet Transplant Registry Rockville, MD: Collaborative Islet Transplant Registry. December 30, 2011:1-186. Available from: https://web.emmes.com/study/isl/reports/ 01062012_7thAnnualReport.pdf.
20. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 2004. 4(4):259-268.
21. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diabetes Rep 2011. 11(5):345-354.
22. Hathout E, Lakey J, Shapiro J. Islet transplant: an option for childhood diabetes? Arch Dis Child 2003. 88(7):591-594.
23. Huurman VA, Hilbrands R, Pinkse GG, Gillard P, Duinkerken G, van de Linde P, van der Meer-Prins PM, Versteeg-van der Voort Maarschalk MF, Verbeeck K, Alizadeh BZ, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. Plos One 2008. 3(6):e2435.
24. Huurman VA, van der Torren CR, Gillard P, Hilbrands R, van der Meer-Prins EP, Duinkerken G, Gorus FK, Claas FH, Keymeulen B, Roelen DL, et al. Immune responses against islet allografts during tapering of immunosuppression-a pilot study in 5 subjects. Clin Exp Immunol 2012. 169(2):190-198.
25. Han D, Xu X, Baidal D, Leith J, Ricordi C, Alejandro R, Kenyon NS. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004. 53(9):2281-2290.
26. Lakey JR, Warnock GL, Rajotte RV, Suarez-Alamazor ME, Ao Z, Shapiro AM, Kneteman NM. Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation 1996. 61(7):1047-1053.
27. Kaddis JS, Danobeitia JS, Niland JC, Stiller T, Fernandez LA. Multicenter analysis of novel and established variables associated with successful human islet isolation outcomes. Am J Transplant 2010. 10(3):646-656.
28. Liu X, Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Yonekawa Y, Nagata H, Kamiya H, Ueda M, Hatanaka N, et al. Analysis of donor-and isolation-related variables from non-heart-beating donors (NHBDs) using the Kyoto islet isolation method. Cell Transplant 2008.17(6):649-656.
29. Hanley SC, Paraskevas S, Rosenberg L. Donor and isolation variables predicting human islet isolation success. Transplantation 2008. 85(7):950-955.
30. Nano R, Clissi B, Melzi R, Calori G, Maffi P, Antonioli B, Marzorati S, Aldrighetti L, Freschi M, Grochowiecki T, et al. Islet isolation for allotransplantation: variables associated with successful islet yield and graft function. Diabetologia 2005. 48(5):906-912.
31. Fraker C, Montelongo J, Szust J, Khan A, Ricordi C. The use of multiparametric monitoring during islet cell isolation and culture: a potential tool for in-process corrections of critical physiological factors. Cell Transplant 2004. 13(5):497-502.
32. Kin T, O'Gorman D, Schroeder A, Onderka C, Richer B, Rosichuk S, Zhai X, Shapiro AM. Human islet distribution program for basic research at a single center. Transplant Proc 2011. 43(9):3195-3197.
33. O'Gorman D, Kin T, Imes S, Pawlick R, Senior P, Shapiro AM. Comparison of human islet isolation outcomes using a new mammalian tissue-free enzyme versus collagenase NB-1. Transplantation 2010. 90(3):255-259.
34. O'Gorman D, Kin T, Murdoch T, Richer B, McGhee-Wilson D, Ryan EA, Shapiro JA, Lakey JR. The standardization of pancreatic donors for islet isolations. Transplantation 2005. 80(6):801-806.
35. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005. 293(7):830-835.
36. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004. 53(4):955-962.
37. Szot GL, Lee MR, Tavakol MM, Lang J, Dekovic F, Kerlan RK, Stock PG, Posselt AM. Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease. Transplantation 2009. 88(6):753-756.
38. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010. 90(12):1595-1601.
39. Posselt AM, Szot GL, Frassetto LA, Masharani U, Stock PG. Clinical islet transplantation at the University of California, San Francisco. Clin Transpl 2010. 2010:235-243.
40. Berney T, Johnson PR. Donor pancreata: evolving approaches to organ allocation for whole pancreas versus islet transplantation. Transplantation 2010. 90(3):238-243.
41. Markmann JF, Deng S, Desai NM, Huang X, Velidedeoglu E, Frank A, Liu C, Brayman KL, Lian MM, Wolf B, et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation 2003. 75(9):1423-1429.
42. Saito T, Gotoh M, Satomi S, Uemoto S, Kenmochi T, Itoh T, Kuroda Y, Yasunami Y, Matsumoto S, Teraoka S, et al. Islet transplantation using donors after cardiac death: report of the Japan Islet Transplantation Registry. Transplantation 2010. 90(7):740-747.
43. Kin T, Shapiro AM. Surgical aspects of human islet isolation. Islets 2010. 2(5):265-273.
44. Paushter DH, Qi M, Danielson KK, Harvat TA, Kinzer K, Barbaro B, Patel S, Hassan SZ, Oberholzer J, Wang Y. Histidine-tryptophan-ketoglutarate and University of Wisconsin solution demonstrate equal effectiveness in the preservation of human pancreata intended for islet isolation: a large-scale, single-center experience. Cell Transplant 2012. In press.
45. Stewart ZA, Cameron AM, Singer AL, Dagher NN, Montgomery RA, Segev DL. Histidine-tryptophanketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant 2009. 9(1):217-221.
46. Becker T, Ringe B, Nyibata M, Meyer zu Vilsendorf A, Schrem H, Luck R, Neipp M, Klempnauer J, Bektas H. Pancreas transplantation with histidine-tryptophanketoglutarate (HTK) solution and University of Wisconsin (UW) solution: is there a difference? JOP 2007. 8(3):304-311.
47. Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM, Rajotte RV. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplant 1999. 8(3):285-292.
48. Hughes SJ, Clark A, McShane P, Contractor HH, Gray DW, Johnson PR. Characterisation of collagen VI within the islet-exocrine interface of the human pancreas: implications for clinical islet isolation? Transplantation 2006. 81(3):423-426.
49. Kin T, Johnson PR, Shapiro AM, Lakey JR. Factors influencing the collagenase digestion phase of human islet isolation. Transplantation 2007. 83(1):7-12.
50. Kin T. Islet isolation for clinical transplantation. Adv Exp Med Biol 2010. 654:683-710.
51. ElSaadany S, Tyshenko MG, Oraby T, Malcolm AJ, Senior P, Shapiro AM, Catford A, Salem T, Wu J, Krewski D, et al. The risk to human islet cell transplant recipients of acquiring variant Creutzfeldt-Jakob disease: a provisional quantitative risk assessment. Transplantation 2011. 92(1):e2-4.
52. Bucher P, Mathe Z, Morel P, Bosco D, Andres A, Kurfuest M, Friedrich O, Raemsch-Guenther N, Buhler LH, Berney T. Assessment of a novel twocomponent enzyme preparation for human islet isolation and transplantation. Transplantation 2005. 79(1):91-97.
53. Brandhorst H, Friberg A, Nilsson B, Andersson HH, Felldin M, Foss A, Salmela K, Tibell A, Tufveson G, Korsgren O, et al. Large-scale comparison of Liberase HI and collagenase NB1 utilized for human islet isolation. Cell Transplant 2010. 19(1):3-8.
54. Kin T, O'Gorman D, Zhai X, Pawlick R, Imes S, Senior P, Shapiro AM. Nonsimultaneous administration of pancreas dissociation enzymes during islet isolation. Transplantation 2009. 87(11):1700-1705.
55. Caballero-Corbalan J, Friberg AS, Brandhorst H, Nilsson B, Andersson HH, Felldin M, Foss A, Salmela K, Tibell A, Tufveson G, et al. Vitacyte collagenase HA: a novel enzyme blend for efficient human islet isolation. Transplantation 2009. 88(12):1400-1402.
56. Robertson GS, Chadwick DR, Contractor H, James RF, London NJ. The optimization of large-scale density gradient isolation of human islets. Acta Diabetol 1993. 30(2):93-98.
57. Swift S, Kin T, Mirbolooki M, Wilson R, Lakey JR. Comparison of cooling systems during islet purification. Cell Transplant 2006. 15(2):175-180.
58. Mita A, Ricordi C, Messinger S, Miki A, Misawa R, Barker S, Molano RD, Haertter R, Khan A, Miyagawa S, et al. Antiproinflammatory effects of iodixanol (OptiPrep)-based density gradient purification on human islet preparations. Cell Transplant 2010. 19(12):1537-1546.
59. Barbaro B, Salehi P, Wang Y, Qi M, Gangemi A, Kuechle J, Hansen MA, Romagnoli T, Avila J, Benedetti E, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007. 84(9):1200-1203.
60. Warnock GL, Meloche RM, Thompson D, Shapiro RJ, Fung M, Ao Z, Ho S, He Z, Dai LJ, Young L, et al. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus. Arch Surg 2005. 140(8):735-744.
61. Miki A, Ricordi C, Messinger S, Yamamoto T, Mita A, Barker S, Haetter R, Khan A, Alejandro R, Ichii H. Toward improving human islet isolation from younger donors: rescue purification is efficient for trapped islets. Cell Transplant 2009. 18(1):13-22.
62. Ichii H, Pileggi A, Molano RD, Baidal DA, Khan A, Kuroda Y, Inverardi L, Goss JA, Alejandro R, Ricordi C. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005. 5(1):21-30.
63. Markmann JF, Tomaszewski J, Posselt AM, Levy MM, Woehrle M, Barker CF, Naji A. The effect of islet cell culture in vitro at 24 degrees C on graft survival and MHC antigen expression. Transplantation 1990. 49(2):272-277.
64. Ichii H, Wang X, Messinger S, Alvarez A, Fraker C, Khan A, Kuroda Y, Inverardi L, Goss JA, Alejandro R, et al. Improved human islet isolation using nicotinamide. Am J Transplant 2006. 6(9):2060-2068.
65. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, Pileggi A, Poggioli R, Ichii H, Khan A, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005. 5(8):2037-2046.
66. Kerr-Conte J, Vandewalle B, Moerman E, Lukowiak B, Gmyr V, Arnalsteen L, Caiazzo R, Sterkers A, Hubert T, Vantyghem MC, et al. Upgrading pretransplant human islet culture technology requires human serum combined with media renewal. Transplantation 2010. 89(9):1154-1160.
67. Clayton H, Turner J, Swift S, James R, Bell P. Supplementation of islet culture medium with insulin may have a beneficial effect on islet secretory function. Pancreas 2001. 22(1):72-74.
68. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Schulz R, Lakey JR, Warnock GL, Rajotte RV. Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. J Clin Endocrinol Metab 1994. 79(4):1058-1062.
69. Gaber AO, Fraga DW, Callicutt CS, Gerling IC, Sabek OM, Kotb MY. Improved in vivo pancreatic islet function after prolonged in vitro islet culture. Transplantation 2001.72(11):1730-1736.
70. Murdoch TB, McGhee-Wilson D, Shapiro AM, Lakey JR. Methods of human islet culture for transplantation. Cell Transplant 2004. 13(6):605-617.
71. Berney T. Islet culture and counter-culture. Commentary on: Effect of short-term culture on functional and stressrelated parameters in isolated human islets by Ihm et al. Transpl Int 2009. 22(5):531-533.
72. Daoud J, Rosenberg L, Tabrizian M. Pancreatic islet culture and preservation strategies: advances, challenges, and future outlook. Cell Transplant 2010. 19(12):1523-1535.
73. Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 1990. 71(1):152-156.
74. Ichii H, Sakuma Y, Pileggi A, Fraker C, Alvarez A, Montelongo J, Szust J, Khan A, Inverardi L, Naziruddin B, et al. Shipment of human islets for transplantation. Am J Transplant 2007. 7(4):1010-1020.
75. Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, Barth M, Froud T, Alejandro R, Ricordi C. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002. 74(12):1761-1766.
76. Goss JA, Goodpastor SE, Brunicardi FC, Barth MH, Soltes GD, Garber AJ, Hamilton DJ, Alejandro R, Ricordi C. Development of a human pancreatic islettransplant program through a collaborative relationship with a remote islet-isolation center. Transplantation 2004. 77(3):462-466.
77. Cabrera O, Jacques-Silva MC, Berman DM, Fachado A, Echeverri F, Poo R, Khan A, Kenyon NS, Ricordi C, Berggren PO, et al. Automated, high-throughput assays for evaluation of human pancreatic islet function. Cell Transplant 2008. 16(10):1039-1048.
78. Ichii H, Inverardi L, Pileggi A, Molano RD, Cabrera O, Caicedo A, Messinger S, Kuroda Y, Berggren PO, Ricordi C. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 2005. 5(7):1635-1645.
79. Papas KK, Colton CK, Nelson RA, Rozak PR, Avgoustiniatos ES, Scott WE, 3rd, Wildey GM, Pisania A, Weir GC, Hering BJ. Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. Am J Transplant 2007. 7(3):707-713.
80. Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab 2006. 8(1):1-7.
81. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995. 18(4):517-522.
82. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971. 1(7712):1253-1257.
83. Mujtaba M, Fridell J, Sharfuddin A, Kandula P, Yaqub MS, Phillips CL, Mishler D, Taber T. BK virus nephropathy in simultaneous pancreas kidney transplant: a potentially preventable cause of kidney allograft loss. Clin Transplant 2012. 26(2):E87-E93.
84. Weimar B, Rauber K, Brendel MD, Bretzel RG, Rau WS. Percutaneous transhepatic catheterization of the portal vein: A combined CT-and fluoroscopy-guided technique. Cardiovasc Intervent Radiol 1999. 22(4):342-344.
85. Venturini M, Angeli E, Maffi P, Fiorina P, Bertuzzi F, Salvioni M, De Cobelli F, Socci C, Aldrighetti L, Losio C, et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology 2005. 234(2):617-624.
86. Villiger P, Ryan EA, Owen R, O'Kelly K, Oberholzer J, Al Saif F, Kin T, Wang H, Larsen I, Blitz SL, et al. Prevention of bleeding after islet transplantation: lessons learned from a multivariate analysis of 132 cases at a single institution. Am J Transplant 2005. 5(12):2992-2998.
87. Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J. Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation. Transplantation 2004. 78(1):172-173.
88. Neeman Z, Hirshberg B, Harlan D, Wood BJ. Radiologic aspects of islet cell transplantation. Curr Diab Rep 2006. 6(4):310-315.
89. Gaba RC, Garcia-Roca R, Oberholzer J. Pancreatic islet cell transplantation: an update for interventional radiologists. J Vasc Interv Radiol 2012. 23(5):583-594.
90. Goss JA, Soltes G, Goodpastor SE, Barth M, Lam R, Brunicardi FC, Froud T, Alejandro R, Ricordi C. Pancreatic islet transplantation: the radiographic approach. Transplantation 2003. 76(1):199-203.
91. Low G, Hussein N, Owen RJ, Toso C, Patel VH, Bhargava R, Shapiro AM. Role of imaging in clinical islet transplantation. Radiographics 2010. 30(2):353-366.
92. Owen RJ, Mercer JR, Al-Saif F, Molinari M, Ashforth RA, Rajotte RV, Conner-Spady B, Shapiro AM. Portal vein embolization with radiolabeled polyvinyl alcohol particles in a swine model: hepatic distribution and implications for pancreatic islet cell transplantation. Cardiovasc Intervent Radiol 2009. 32(3):499-507.
93. Owen RJ, Ryan EA, O'Kelly K, Lakey JR, McCarthy MC, Paty BW, Bigam DL, Kneteman NM, Korbutt GS, Rajotte RV, et al. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology 2003. 229(1):165-170.
94. Baidal DA, Froud T, Ferreira JV, Khan A, Alejandro R, Ricordi C. The bag method for islet cell infusion. Cell Transplant 2003. 12(7):809-813.
95. Kawahara T, Kin T, Kashkoush S, Gala-Lopez B, Bigam DL, Kneteman NM, Koh A, Senior PA, Shapiro AM. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant 2011. 11(12):2700-2707.
96. Froud T, Yrizarry JM, Alejandro R, Ricordi C. Use of D-STAT to prevent bleeding following percutaneous transhepatic intraportal islet transplantation. Cell Transplant 2004. 13(1):55-59.
97. Kawahara T, Kin T, Shapiro AM. A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation. J Hepatobiliary Pancreat Sci 2012. 19(3):281-288.
98. Ohansson H, Lukinius A, Moberg L, Lundgren T, Berne C, Foss A, Felldin M, Kallen R, Salmela K, Tibell A, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005. 54(6):1755-1762.
99. Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 2010. 89(4):465-471.
100. Hirshberg B, Rother KI, Digon BJ 3rd, Lee J, Gaglia JL, Hines K, Read EJ, Chang R, Wood BJ, Harlan DM. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 2003. 26(12):3288-3295.
101. Ryan EA, Paty BW, Senior PA, Shapiro AM. Risks and side effects of islet transplantation. Curr Diabetes Rep 2004. 4(4):304-309.
102. Kawahara T, Kin T, Kashkoush S, Gala-Lopez B, Bigam DL, Kneteman NM, Koh A, Senior PA, Shapiro AM. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant 2011. 11(12):2700-2707.
103. Kawahara T, Kin T, Shapiro AM. A comparison of islet autotransplantation with allotransplantation and factors elevating acute portal pressure in clinical islet transplantation. J Hepatobiliary Pancreat Sci 2012. 19(3):281-288.
104. Rafael E, Ryan EA, Paty BW, Oberholzer J, Imes S, Senior P, McDonald C, Lakey JR, Shapiro AM. Changes in liver enzymes after clinical islet transplantation. Transplantation 2003. 76(9):1280-1284.
105. Bhargava R, Senior PA, Ackerman TE, Ryan EA, Paty BW, Lakey JR, Shapiro AM. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004. 53(5):1311-1317.
106. Maffi P, Angeli E, Bertuzzi F, Paties C, Socci C, Fedeli C, De Taddeo F, Nano R, Di Carlo V, Del Maschio A, et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant 2005. 14(10):727-733.
107. Markmann JF, Rosen M, Siegelman ES, Soulen MC, Deng S, Barker CF, Naji A. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes 2003. 52(7):1591-1594.
108. Low G, Hussein N, Owen RJ, Toso C, Patel VH, Bhargava R, Shapiro AM. Role of imaging in clinical islet transplantation. Radiographics 2010. 30(2):353-366.
109. Toso C, Isse K, Demetris AJ, Dinyari P, Koh A, Imes S, Kin T, Emamaullee J, Senior P, Shapiro AM. Histologic graft assessment after clinical islet transplantation. Transplantation 2009. 88(11):1286-1293.
110. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997. 150(3):1071-1087.
111. Dombrowski F, Mathieu C, Evert M. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 2006. 66(3):1833-1843.
112. Najarian JS, Sutherland DE, Matas AJ, Goetz FC. Human islet autotransplantation following pancreatectomy. Transplant Proc 1979. 11(1):336-340.
113. Najarian JS, Sutherland DE, Matas AJ, Steffes MW, Simmons RL, Goetz FC. Human islet transplantation: a preliminary report. Transplant Proc 1977. 9(1):233-236.
114. Sutherland DE, Matas AJ, Najarian JS. Pancreas and islet transplantation. World J Surg 1977. 2(1):185-195.
115. Humar A, Fishman JA. Donor-derived infection: old problem, new solutions? Am J Transplant 2008. 8(6):1087-1088.
116. Len O, Gavalda J, Blanes M, Montejo M, San Juan R, Moreno A, Carratala J, de la Torre-Cisneros J, Bou G, Cordero E, et al. Donor infection and transmission to the recipient of a solid allograft. Am J Transplant 2008. 8(11):2420-2425.
117. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005. 352(11):1103-1111.
118. Morris MI, Fischer SA, Ison MG. Infections transmitted by transplantation. Infect Dis Clin North Am 2010. 24(2):497-514.
119. Barshes NR, Agee EE, Zgabay T, Brunicardi FC, Goss JA, DeBakey ME. West Nile Virus encephalopathy following pancreatic islet transplantation. Am J Transplant 2006. 6(12):3037.
120. Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Schweitzer E, Ganz S, Caliendo A, Orlowski JP, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant 2010. 10(4):889-899.
121. Senior P, Kin T, Shapiro J, Koh A. Islet transplantation at the University of Alberta: status update and review of progress over the last decade. Canad J Diabetes 2012. 36(1):32-37.
122. Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011. 92(3):303-310.
123. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005. 80(6):749-758.
124. Geissler EK, Schlitt HJ. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 2010. 78(11):1075-1079.
125. Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc 2010. 42(4):1314-1316.
126. Feldmeyer L, Hofbauer GF, Boni T, French LE, Hafner J. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Brit J Dermatol 2012. 166(2):422-424.
127. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012. 12(5):1146-1156.
128. Geissler EK, Schlitt HJ. Transplantation: can sirolimus prevent skin cancer in transplant recipients? Nat Rev Nephrol 2010. 6(11):639-641.
129. Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, Zafrani ES, Mallat A, Duvoux C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis 2012. 44(7):610-616.
130. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a metaanalysis. Liver Transplant 2012. 18(1):62-69.
131. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010. 51(4):1237-1243.
132. Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, Imes S, Halpin A, Ryan EA, Shapiro AM. High risk of sensitization after failed islet transplantation. Am J Transplant 2007. 7(10):2311-2317.
133. Ferrari-Lacraz S, Berney T, Morel P, Marangon N, Hadaya K, Demuylder-Mischler S, Pongratz G, Pernin N, Villard J. Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 2008. 86(2):357-359.
134. Moreau F, Toti F, Bayle F, Berney T, Egelhofer H, Chastre M, Richard MJ, Greget M, Masson D, Zobairi F, et al. Rescue of a pancreatic islet graft after steroid therapy. Transplantation 2012. 93(3):e10-11.
135. Kessler L, Parissiadis A, Bayle F, Moreau F, Pinget M, Froelich N, Cazenave JP, Berney T, Benhamou PY, Hanau D, et al. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009. 9(8):1961-1966.
136. Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, von Graffenried B, Wolfe BM. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984. 223(4643):1362-1367.
137. Sutherland DE, Sibley R, Xu XZ, Michael A, Srikanta AM, Taub F, Najarian J, Goetz FC. Twin-totwin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984. 97:80-87.
138. Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001. 233(4):463-501.
139. Burke GW 3rd, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr Diabetes Rep 2011. 11(5):413-419.
140. Worcester Human Islet Transplantation Group. Autoimmunity after islet-cell allotransplantation. N Engl J Med 2006. 355(13):1397-1399.
141. Markees TG, Serreze DV, Phillips NE, Sorli CH, Gordon EJ, Shultz LD, Noelle RJ, Woda BA, Greiner DL, Mordes JP, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999. 48(5):967-974.
142. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005. 23(2):115-126.
143. Hilbrands R, Huurman VA, Gillard P, Velthuis JH, De Waele M, Mathieu C, Kaufman L, Pipeleers-Marichal M, Ling Z, Movahedi B, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009. 58(10):2267-2276.
144. Chatenoud L. Chemical immunosuppression in islet transplantation-friend or foe? N Engl J Med 2008. 358(11):1192-1193.
145. Desai NM, Goss JA, Deng S, Wolf BA, Markmann E, Palanjian M, Shock AP, Feliciano S, Brunicardi FC, Barker CF, et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity? Transplantation 2003. 76(11):1623-1625.
146. Shapiro AM, Gallant HL, Hao EG, Lakey JR, McCready T, Rajotte RV, Yatscoff RW, Kneteman NM. The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 2005. 27(1):35-37.
147. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007. 117(9):2553-2561.
148. Bellin MD, Barton FB, Heitman A, Harmon JV, Kandaswamy R, Balamurugan AN, Sutherland DE, Alejandro R, Hering BJ. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012. 12(6):1576-1583.
149. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012. 35(7):1436-1445.
150. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010. 33(4):826-832.
151. Bellin MD, Barton FB, Heitman A, Harmon J, Balamurugan AN, Kandaswamy R, Sutherland DE, Alejandro R, Hering BJ. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012. 12(6):1576-1583.
152. Bellin MD, Kandaswamy R, Parkey J, Zhang HJ, Liu B, Ihm SH, Ansite JD, Witson J, Bansal-Pakala P, Balamurugan AN, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008. 8(11):2463-2470.
153. Hering BJ. Achieving and maintaining insulin independence in human islet transplant recipients. Transplantation 2005. 79(10):1296-1297.
154. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, et al. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 2009. 58(10):2277-2284.
155. Ildstad ST, Chilton PM, Xu H, Domenick MA, Ray MB. Preconditioning of NOD mice with anti-CD8 mAb and costimulatory blockade enhances chimerism and tolerance and prevents diabetes, while depletion of alpha beta-TCR+ and CD4+ cells negates the effect. Blood 2005. 105(6):2577-2584.
156. Glandt M, Herold KC. Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation. Curr Diabetes Rep 2004. 4(4):291-297.
157. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2012. 2(4):a007781.
158. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat Med 2012. 18(1):48-53.
159. Clatworthy MR, Friend PJ, Calne RY, Rebello PR, Hale G, Waldmann H, Watson CJ. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 2009. 87(7):1092-1095.
160. Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005. 5(6):1347-1353.
161. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998. 351(9117):1701-1702.
162. Newell KA, Cendales LC, Kirk AD. Finding the right job for the tool: alemtuzumab and its role in renal transplantation. Am J Transplant 2008. 8(7):1363-1364.
163. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003. 76(1):120-129.
164. Knechtle SJ, Pirsch JD, H. Fechner J J, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003. 3(6):722-730.
165. Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004. 136(4):754-760.
166. Gala-Lopez BL, Senior PA, Koh A, Kashkoush SM, Kawahara T, Kin T, Humar A, Shapiro AM. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. Am J Transplant 2011. 11(12):2708-2714.
167. Toso C, Edgar R, Pawlick R, Emamaullee J, Merani S, Dinyari P, Mueller TF, Shapiro AM, Anderson CC. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transplant Int 2009. 22(2):182-191.
168. Hafiz MM, Poggioli R, Caulfield A, Messinger S, Geiger MC, Baidal DA, Froud T, Ferreira JV, Tzakis AG, Ricordi C, et al. Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. Am J Transplant 2004. 4(10):1697-1702.
169. Farney AC, Xenos E, Sutherland DE, Widmer M, Stephanian E, Field MJ, Kaufman DB, Stevens RB, Blazar B, Platt J, et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993. 25(1 Pt 2):865-866.
170. McCall M, Pawlick R, Kin T, Shapiro AM. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant 2012. 12(2):322-329.
171. Matsumoto S, Takita M, Chaussabel D, Noguchi H, Shimoda M, Sugimoto K, Itoh T, Chujo D, Sorelle J, Onaca N, et al. Improving efficacy of clinical islet transplantation with Iodixanol based islet purification, thymoglobulin induction and blockage of IL-1-beta and TNFalpha. Cell Transplant 2011. 20(10):1641-1647.
172. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Kallen R, Ostraat O, Salmela K, Tibell A, Tufveson G, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002. 360(9350):2039-2045.
173. Nilsson B, Ekdahl KN, Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant 2011. 16(6):620-626.
174. Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, Felldin M, Foss A, Kyllonen L, Langstrom B, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant 2009. 9(12):2816-2824.
175. Eich T, Eriksson O, Lundgren T. Visualization of early engraftment in clinical islet transplantation by positronemission tomography. N Engl J Med 2007. 356(26):2754-2755.
176. Cabric S, Sanchez J, Lundgren T, Foss A, Felldin M, Kallen R, Salmela K, Tibell A, Tufveson G, Larsson R, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007. 56(8):2008-2015.
177. Emamaullee JA, Shapiro AM. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006. 55(7):1907-1914.
178. Emamaullee JA, Rajotte RV, Liston P, Korneluk RG, Lakey JR, Shapiro AM, Elliott JF. XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 2005. 54(9):2541-2548.
179. Emamaullee J, Liston P, Korneluk RG, Shapiro AM, Elliott JF. XIAP overexpression in islet beta-cells enhances engraftment and minimizes hypoxia-reperfusion injury. Am J Transplant 2005. 5(6):1297-1305.
180. Emamaullee JA, Stanton L, Schur C, Shapiro AM. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 2007. 56(5):1289-1298.
181. Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, Cai SX, Tseng B, Shapiro AM. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes 2008. 57(6):1556-1566.
182. Emamaullee JA, Davis J, Pawlick R, Toso C, Merani S, Cai SX, Tseng B, Shapiro AM. Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival. Diabetes 2010. 59(6):1469-1477.
183. McCall M, Toso C, Emamaullee J, Pawlick R, Edgar R, Davis J, Maciver A, Kin T, Arch R, Shapiro AM. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 2011. 150(1):48-55.
184. Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D, Tharavanij T, Mendez AJ, Ricordi C, Alejandro R. Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction. Cell Transplant 2009. 18(10):1247-1259.
185. Froud T, Ricordi C, Alejandro R. Exenatide Use in Islet Transplantation-Reasons to Remain Optimistic. Transplantation 2009. 87(1):154.
186. Rickels MR, Naji A. Exenatide use in islet transplantation: words of caution. Transplantation 2009. 87(1):153.
187. Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, Mineo D, Baidal DA, Cure P, Ponte G, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 2008. 86(12):1658-1665.
188. Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, Cure PE, Monroy K, Mendez A, Selvaggi G, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008. 86(1):36-45.
189. Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007. 83(1):24-28.
190. Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, Qi M, Wang Y, Pallan P, Owens C, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008. 8(6):1250-1261.
191. Merani S, Truong W, Emamaullee JA, Toso C, Knudsen LB, Shapiro AM. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 2008. 149(9):4322-4328.
192. Emamaullee JA, Merani S, Toso C, Kin T, Al-Saif F, Truong W, Pawlick R, Davis J, Edgar R, Lock J, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 2009. 150(5):2145-2152.
193. Toso C, McCall M, Emamaullee J, Merani S, Davis J, Edgar R, Pawlick R, Kin T, Knudsen LB, Shapiro AM. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transplant Int 2010. 23(3):259-265.
194. Berney T. Liraglutide in islet transplantation: from bench to bedside. Transplant Int 2010. 23(3):257-258.
195. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003. 349(10):931-940.
196. Leitao CB, Cure P, Messinger S, Pileggi A, Lenz O, Froud T, Faradji RN, Selvaggi G, Kupin W, Ricordi C, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation 2009. 87(5):681-688.
197. Shapiro AM, Lakey JR, Paty BW, Senior PA, Bigam DL, Ryan EA. Strategic opportunities in clinical islet transplantation. Transplantation 2005. 79(10):1304-1307.
198. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006. 355(13):1318-1330.
199. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003. 362(9391):1242.
200. Berney T, Secchi A. Rapamycin in islet transplantation: friend or foe? Transplant Int 2009. 22(2):153-161.
201. Alfadhli E, Koh A, Albaker W, Bhargava R, Ackerman T, McDonald C, Ryan EA, Shapiro AM, Senior PA. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transplant Int 2009. 22(6):622-625.
202. Del Olmo Garcia MI, Lauriola V, Gomez Aracena A, Messinger S, Corrales A, Ricordi C, Alejandro R. Alterations of the female reproductive system in islet recipient receiving immunosuppression. Cell Transplant 2011. 20(10):1649-1651.
203. Cure P, Pileggi A, Froud T, Norris PM, Baidal DA, Cornejo A, Hafiz MM, Ponte G, Poggioli R, Yu J, et al. Alterations of the female reproductive system in recipients of islet grafts. Transplantation 2004. 78(11):1576-1581.
204. Molinari M, Al-Saif F, Ryan EA, Lakey JR, Senior PA, Paty BW, Bigam DL, Kneteman NM, Shapiro AM. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005. 5(11):2799-2804.
205. Digon BJ 3rd, Rother KI, Hirshberg B, Harlan DM. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care 2003. 26(11):3191.
206. Senior PA, Shapiro AM, Ackerman TE, Ryan EA, Paty BW, Bhargava R. Magnetic resonance-defined perinephric edema after clinical islet transplantation: a benign finding associated with mild renal impairment. Transplantation 2004. 78(6):945-948.
207. Leitao CB, Froud T, Cure P, Tharavanij T, Pileggi A, Ricordi C, Alejandro R. Nonalbumin proteinuria in islet transplant recipients. Cell Transplant 2010. 19(1):119-125.
208. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005. 5(9):2318-2323.
209. Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, Adams AB, Sears MH, Bowen PH, Kirk AD, et al. Experience with a novel efalizumabbased immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant 2010. 10(9):2082-2091.
210. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011. 65(3):546-551.
211. Gadzia J, Turner J. Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drug Dermatol 2010. 9(8):1005-1009.
212. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibodyassociated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009. 10(8):816-824.
213. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005. 54(7):2060-2069.
214. Tiwari JL, Schneider B, Barton F, Anderson SA. Islet cell transplantation in type 1 diabetes: an analysis of efficacy outcomes and considerations for trial designs. Am J Transplant 2012. 12(7):1898-907.
215. Berney T, Ferrari-Lacraz S, Buhler L, Oberholzer J, Marangon N, Philippe J, Villard J, Morel P. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am J Transplant 2009. 9(2):419-423.
216. Gibly RF, Graham JG, Luo X, Lowe WL Jr, Hering BJ, Shea LD. Advancing islet transplantation: from engraftment to the immune response. Diabetologia 2011. 54(10):2494-2505.
217. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011. 8(1):6-16.
218. Payne WD, Sutherland DE, Matas AJ, Najarian JS. Amelioration of diabetes in rats by transplantation of islet tissue from a single donor to multiple recipients. Surg Forum 1977. 28:301-304.
219. Griffin SM, Alderson D, Farndon JR. Comparison of harvesting methods for islet transplantation. Brit J Surg 1986. 73(9):712-715.
220. Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H, Yonekawa Y, Yamada Y, Fukuda K, Tsukiyama K, Suzuki H, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005. 365(9471):1642-1644.
221. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004. 4(3):295-298.
222. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997. 46(2):271-286.
223. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993. 329(14):977-986.
224. Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant 2010. 15(1):119-123.
225. Lee TC, Barshes NR, Agee EE, O'Mahoney CA, Brunicardi FC, Goss JA. The effect of whole organ pancreas transplantation and PIT on diabetic complications. Curr Diabetes Rep 2006. 6(4):323-327.
226. Luzi L. Pancreas transplantation and diabetic complications. N Engl J Med 1998. 339(2):115-117.
227. Becker BN, Brazy PC, Becker YT, Odorico JS, Pintar TJ, Collins BH, Pirsch JD, Leverson GE, Heisey DM, Sollinger HW. Simultaneous pancreas-kidney transplantation reduces excess mortality in type 1 diabetic patients with end-stage renal disease. Kidney Int 2000. 57(5):2129-2135.
228. Smets YF, Westendorp RG, van der Pijl JW, de Charro FT, Ringers J, de Fijter JW, Lemkes HH. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and endstage renal failure. Lancet 1999. 353(9168):1915-1919.
229. Tyden G, Bolinder J, Solders G, Brattstrom C, Tibell A, Groth CG. Improved survival in patients with insulindependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 1999. 67(5):645-648.
230. Giannarelli R, Coppelli A, Sartini MS, Del Chiaro M, Vistoli F, Rizzo G, Barsotti M, Del Prato S, Mosca F, Boggi U, et al. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia 2006. 49(12):2977-2982.
231. Koznarova R, Saudek F, Sosna T, Adamec M, Jedinakova T, Boucek P, Bartos V, Lanska V. Beneficial effect of pancreas and kidney transplantation on advanced diabetic retinopathy. Cell Transplant 2000. 9(6):903-908.
232. Fioretto P, Mauer M. Reversal of diabetic nephropathy: lessons from pancreas transplantation. J Nephrol 2012. 25(1):13-18.
233. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998. 339(2):69-75.
234. Kendall DM, Rooney DP, Smets YF, Salazar Bolding L, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type I diabetes and autonomic neuropathy. Diabetes 1997. 46(2):249-257.
235. Larsen JL, Ratanasuwan T, Burkman T, Lynch T, Erickson J, Colling C, Lane J, Mack-Shipman L, Lyden E, Loseke M, et al. Carotid intima media thickness decreases after pancreas transplantation. Transplantation 2002. 73(6):936-940.
236. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A, Magee JC, Cibrik D, Wolfe RA, Port FK, Agodoa L, Kaufman DB, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001. 71(1):82-90.
237. Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J Transplant 2008. 8(10):1990-1997.
238. Del Carro U, Fiorina P, Amadio S, De Toni Franceschini L, Petrelli A, Menini S, Martinelli Boneschi F, Ferrari S, Pugliese G, Maffi P, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007. 30(12):3063-3069.
239. Venturini M, Fiorina P, Maffi P, Losio C, Vergani A, Secchi A, Del Maschio A. Early increase of retinal arterial and venous blood flow velocities at color Doppler imaging in brittle type 1 diabetes after islet transplant alone. Transplantation 2006. 81(9):1274-1277.
240. Fiorina P, Gremizzi C, Maffi P, Caldara R, Tavano D, Monti L, Socci C, Folli F, Fazio F, Astorri E, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005. 28(6):1358-1365.
241. Fiorina P, Folli F, Zerbini G, Maffi P, Gremizzi C, Di Carlo V, Socci C, Bertuzzi F, Kashgarian M, Secchi A. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003. 14(8):2150-2158.
242. Fiorina P, Folli F, Maffi P, Placidi C, Venturini M, Finzi G, Bertuzzi F, Davalli A, D'Angelo A, Socci C, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003. 75(8):1296-1301.
243. Fiorina P, Folli F, Bertuzzi F, Maffi P, Finzi G, Venturini M, Socci C, Davalli A, Orsenigo E, Monti L, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidneytransplanted patients. Diabetes Care 2003. 26(4):1129-1136.
244. Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, Ho S, Worsley D, Fung M, Meneilly G, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011. 91(3):373-378.
245. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, Johnson JD, Verchere CB, Partovi N, Begg IS, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008. 86(12):1762-1766.
246. Danielson KK, Hatipoglu B, Kinzer K, Kaplan B, Martellotto J, Qi M, Mele A, Benedetti E, Oberholzer J. Reduction in carotid intima-media thickness after pancreatic islet transplantation in patients with type 1 diabetes. Diabetes Care 2012. In press.
247. McCall MD, Toso C, Baetge EE, Shapiro AM. Are stem cells a cure for diabetes? Clin Sci 2010. 118(2):87-97.
248. Herold KC, Bluestone JA. Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med 2011. 3(95):95fs1.
249. Voltarelli JC, Couri CE. Stem cell transplantation for type 1 diabetes mellitus. Diabetol Metabol Syndr 2009. 1(1):4.
250. Fiorina P, Voltarelli J, Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev 2011. 32(6):725-754.
251. De Santis GC, de Pina Almeida Prado B Jr, de Lima Prata K, Brunetta DM, Orellana MD, Palma PV, Oliveira MC, Simoes BP, Voltarelli JC, Covas DT. Mobilization and harvesting of PBPC in newly diagnosed type 1 diabetes mellitus. Bone Marrow Transplant 2012. 47(7):993-994.
252. Vantyghem MC, Raverdy V, Balavoine AS, Defrance F, Caiazzo R, Arnalsteen L, Gmyr V, Hazzan M, Noel C, Kerr-Conte J, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3). J Clin Endocrinol Metab 2012. 97(11):E2078-E2083.
253. Berney T, Korsgren O, Posselt A, Pileggi A. Islet transplantation and beta-cell replacement therapies for diabetes. J Transplant 2011. 2011:157840.
254. Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, Frank A, Markmann E, Palanjian M, Brayman K, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003. 237(6):741-749.
255. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 2010. 10(8):1870-1880.
256. Matsumoto S, Takita M, Chaussabel D, Noguchi H, Shimoda M, Sugimoto K, Itoh T, Chujo D, Sorelle J, Onaca N, et al. Improving Efficacy of Clinical Islet Transplantation With Iodixanol-Based Islet Purification, Thymoglobulin Induction, and Blockage of IL-1beta and TNFalpha. Cell Transplant 2011. 20(10):1641-1647.